Abeona Therapeutics (ABEO) Operating Expenses (2011 - 2026)

Abeona Therapeutics' Operating Expenses history runs 16 years deep, the most recent figure standing at $31.8 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 60.96% year-over-year to $31.8 million in Q1 2026; TTM through Mar 2026 was $107.3 million, a 54.14% increase from a year earlier, with the FY2025 full-year figure at $95.3 million, up 48.37% from the prior year.
• Operating Expenses improved to $31.8 million in Q1 2026 per ABEO's latest filing, from $28.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $31.8 million in Q1 2026 and bottomed at $9.0 million in Q2 2022.
• The 5-year median for Operating Expenses is $15.3 million (2024), against an average of $17.3 million.
• Across the five-year window, Operating Expenses slumped 73.81% in 2022 and surged 69.93% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $13.0 million in 2022, then rose by 1.58% to $13.2 million in 2023, then climbed by 26.22% to $16.7 million in 2024, then jumped by 69.93% to $28.3 million in 2025, then increased by 12.08% to $31.8 million in 2026.
• Per Business Quant, the three latest ABEO Operating Expenses figures stand at $31.8 million (Q1 2026), $28.3 million (Q4 2025), and $24.0 million (Q3 2025).